VOLITIONRX LTD (VNRX)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$0.35-0.09%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
Intact: The reason to own it still holds.
VolitionRx grew revenue 300% in Q1 2026. It improved operating income by $949K. The company focuses on partnerships to grow sales. It manages costs to improve finances.
The company lost money and faces regulatory problems. It sold shares at a discount. Revenue is small at $1.7 million in 2025. The stock fell 61% from its high.
The price is about 37% above our fair value near $1. Analysts expect 76% revenue growth. We see risk from losses and regulatory issues.
Breaks if: Operating loss worsens beyond -$6.3M next quarter
Breaks if: Fails to meet NYSE listing requirements
Breaks if: Revenue falls below $191,657 next quarter
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating a volatile management situation and is loss-making, which adds to the uncertainty of its long-term thesis.
The market appears to have priced in a low level of fragility, with a valuation that is cheap compared to peers. However, there is an expectations gap, suggesting that the market may not fully anticipate the challenges ahead.
Fundamentally, VNRX's trajectory is mixed. Recent revenue growth from licensing agreements shows promise, but the risk of an earnings miss is elevated, particularly given its history of consecutive misses.
The future of VNRX hinges on its ability to expand commercial licensing agreements and regain compliance with NYSE standards. Additionally, the performance of larger healthcare companies could influence VNRX's momentum in the sector.
Over the next 1 to 3 years, VNRX will need to navigate its operational challenges while capitalizing on sector trends. Not investment advice.
The most important moves since the prior daily snapshot.
Our read has weakened. It is challenged by expand commercial licensing agreements and milestone revenue.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.